ALSO NOTED: FDA clears BMS' Abilify for youth use; Teva to create 165 jobs in Ireland;

> The Otsuka Pharmaceutical/Bristol-Myers Squibb antipsychotic drug Abilify got the FDA nod for use in bipolar patients 10 to 17 years old. Report [1]

> Teva Pharmaceutical plans to create more than 165 new jobs over the next five years at its IVAX facility in Waterford, Ireland, which researches and makes respiratory products. Report [2]

> FDA warned asthma and emphysema patients not to swallow Spiriva and Foradil capsules, which are designed to be used with inhalers rather than orally. Report [3]

> A Massachusetts judge fined Medtronic $10 million for unacceptable tactics during a patent-infringement trial. Report [4]

> Biovail founder--and largest shareholder--Eugene Melnyk (photo [5]) isn't happy with the company's management, and he's going to do something about it. In a scathing letter [6] to shareholders, Melnyk lambastes the current board of directors for, as he says, not helping the company realize the full potential of its drug delivery technology. Report [7]

> Alnylam is offering up the first signs that RNAi therapy may work in humans. Report [8]

> GlaxoSmithKline has halted work on Dacart after a Phase III trial showed the malaria drug causes anemia in some patients. Report [9]

And Finally... Connecticut ranks second in the nation for its use of antipsychotic drugs in nursing home residents who don't have psychotic disorders. Report [10]